Bortezomib Against Refractory Antibody-Mediated Rejection After ABO-Incompatible Living-Donor Liver Transplantation: Dramatic Effect in Acute-Phase?

Antibody-mediated rejection (AMR) is a refractory rejection after donor-specific antibody-positive or ABO blood-type incompatible (ABOi) organ transplantation. Rituximab dramatically improved the outcome of ABOi living-donor liver transplantation (LDLT); however, an effective treatment for posttrans...

Descrición completa

Detalles Bibliográficos

Principais autores:	Tetsuya Tajima, MD, Koichiro Hata, MD, PhD, Hideaki Okajima, MD, PhD, Momoko Nishikori, MD, PhD, Kentaro Yasuchika, MD, PhD, Jiro Kusakabe, MD, Atsushi Yoshizawa, MD, PhD, Ken Fukumitsu, MD, PhD, Takayuki Anazawa, MD, PhD, Hirokazu Tanaka, MD, Seidai Wada, MD, PhD, Junshi Doi, MD, Akifumi Takaori-Kondo, MD, PhD, Shinji Uemoto, MD, PhD
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wolters Kluwer 2019-10-01
Series:	Transplantation Direct
Acceso en liña:	http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000000932
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!